The influence of angiogenesis research on management of patients with breast cancer.

abstract：:Preclinical and epidemiologic evidence supports a possible role for beta-adrenergic blocking drugs (beta-blockers), and angiotensin-converting enzyme inhibitors (ACEIs) in promoting survival after breast cancer. However, these drugs are often used concurrently with aspirin, and there is a growing body of evidence indi...

journal_title：Breast cancer research and treatment

authors： Holmes MD,Hankinson SE,Feskanich D,Chen WY

更新日期：2013-06-01 00:00:00

abstract：:Genetic risk prediction models such as BRCAPRO are used routinely in genetic counseling for identification of potential BRCA1 and BRCA2 mutation carriers. They require extensive information on the counselee and her family history, and thus are not practical for primary care. To address this gap, we develop and test a ...

journal_title：Breast cancer research and treatment

authors： Biswas S,Atienza P,Chipman J,Blackford AL,Arun B,Hughes K,Parmigiani G

更新日期：2016-01-01 00:00:00

abstract：:Droloxifene, a new antiestrogen, has theoretical advantages over tamoxifen based on preclinical data. These include higher affinity to the estrogen receptor, higher antiestrogenic to estrogenic ratio, and more effective inhibition of cell growth and division in ER positive cell lines, as well as less toxicity, includi...

journal_title：Breast cancer research and treatment

authors： Rauschning W,Pritchard KI

更新日期：1994-01-01 00:00:00

abstract：:Bone metastasis is a common and serious complication in advanced cancers such as breast cancer, prostate cancer, and multiple myeloma. Agents that prevent bone loss could be used to develop an alternative therapy for bone metastasis. RANKL, a member of the tumor necrosis factor superfamily, has been shown to play a si...

journal_title：Breast cancer research and treatment

authors： Zhai Z,Qu X,Yan W,Li H,Liu G,Liu X,Tang T,Qin A,Dai K

更新日期：2014-02-01 00:00:00

abstract：:The activity of selective estrogen receptor modulators (SERMs) is not fully explained by an estrogen receptor (ER) switch model that simply turns estrogen activity on or off. A better understanding of the mechanisms involved in estrogen signaling and the development of drug resistance could help stratify patients into...

journal_title：Breast cancer research and treatment

authors： McCafferty MP,McNeill RE,Miller N,Kerin MJ

更新日期：2009-08-01 00:00:00

abstract：BACKGROUND:There are concerns regarding local toxicity when IORT is applied in Asian women with a smaller breast volume than that of Western women. Trials are required to develop safety profiles for this technique. The aim of this trial was to evaluate acute toxicity after intra-operative radiotherapy (IORT) with low-e...

journal_title：Breast cancer research and treatment

authors： Ahn SG,Bae SJ,Lee HW,Yoon CI,Kim JW,Lee IJ,Jeong J

更新日期：2019-02-01 00:00:00

abstract：:We have previously shown that human breast carcinoma cells demonstrating an interconverted phenotype, where keratin (epithelial marker) and vimentin (mesenchymal marker) intermediate filaments are both expressed, have an increased ability to invade a basement membrane matrix in vitro. This increase in invasive potenti...

journal_title：Breast cancer research and treatment

authors： Kirschmann DA,Seftor EA,Nieva DR,Mariano EA,Hendrix MJ

更新日期：1999-05-01 00:00:00

abstract：:As the number of women surviving breast cancer increases, with implications for the health system, research into the physical and psychosocial sequelae of the cancer and its treatment is a priority. This research estimated self-reported health-related quality of life (HRQoL) associated with two rehabilitation interven...

journal_title：Breast cancer research and treatment

authors： Gordon LG,Battistutta D,Scuffham P,Tweeddale M,Newman B

更新日期：2005-10-01 00:00:00

abstract：:Mutations in the BRCA1 and BRCA2 genes account for the majority of hereditary breast ovarian cancer (HBOC) cases. However, after BRCA1 and BRCA2 screening still the most HBOC cases remain negative for any mutational event. Accordingly, in these cases raises the relevance to analyze the unusual BRCA1/2 variants of unce...

journal_title：Breast cancer research and treatment

authors： Konecny M,Vizvaryova M,Zavodna K,Behulova R,Gerykova Bujalkova M,Krivulcik T,Cisarik F,Kausitz J,Weismanova E

更新日期：2010-01-01 00:00:00

abstract：:Genome-wide Association Studies (GWAS) revealed novel genetic markers for breast cancer susceptibility. But little is known about the risk factors and molecular events associated with breast cancer in Arab Population. Therefore, we designed a broad study to investigate the susceptibility and prognostic implications of...

journal_title：Breast cancer research and treatment

authors： Shan J,Mahfoudh W,Dsouza SP,Hassen E,Bouaouina N,Abdelhak S,Benhadjayed A,Memmi H,Mathew RA,Aigha II,Gabbouj S,Remadi Y,Chouchane L

更新日期：2012-10-01 00:00:00

abstract：:We investigated the role of glial cell line-derived neurotrophic factor (GDNF) in compensating trastuzumab (TZMB)-induced apoptosis in HER2+ breast cancer (BC) cells using xenograft tumors. We generated BC xenografts in nude mice using samples from three patients selected based on their HER2 status and response to TZM...

journal_title：Breast cancer research and treatment

authors： Gardaneh M,Shojaei S,Kaviani A,Behnam B

更新日期：2017-04-01 00:00:00

abstract：:Medroxyprogesterone acetate (MPA) is well recognized to have beneficial effects for the treatment of advanced breast cancer which are comparable to those achieved with other forms of endocrine therapy. Using mammary tumors induced in the rat by dimethylbenz(a)anthracene (DMBA) as a model, we have studied the possibili...

journal_title：Breast cancer research and treatment

authors： Labrie F,Li S,Bélanger A,Côté J,Mérand Y,Lepage M

更新日期：1993-01-01 00:00:00

abstract：PURPOSE:Combining molecular therapies with chemotherapy may offer an improved clinical outcome for chemoresistant tumours. Sphingosine-1-phosphate (S1P) receptor antagonist and sphingosine kinase 1 (SK1) inhibitor FTY720 (FTY) has promising anticancer properties, however, it causes systemic lymphopenia which impairs it...

journal_title：Breast cancer research and treatment

authors： Alshaker H,Wang Q,Srivats S,Chao Y,Cooper C,Pchejetski D

更新日期：2017-10-01 00:00:00

abstract：:Heregulin (HRG) and 17beta-estradiol (E2) interactions that modulate growth of breast cancer cell lines have recently been demonstrated. We examined the ability of heregulin beta1 (HRGbeta1) and 17beta-estradiol to modulate the biological behavior of estrogen receptor (ER) negative human breast cancer cell lines (AU-5...

journal_title：Breast cancer research and treatment

authors： Yoo JY,Lessor T,Hamburger AW

更新日期：1998-09-01 00:00:00

abstract：:Pathological complete response (pCR) is an important predictor of long-term survival in patients with breast cancer receiving neoadjuvant chemotherapy (NAC). At present, the accuracy of traditional radiological assessments during treatment in predicting pCR is poor. Unidimensional and 3D volumetric ultrasound measurem...

journal_title：Breast cancer research and treatment

authors： Gounaris I,Provenzano E,Vallier AL,Hiller L,Iddawela M,Hilborne S,Taylor K,Britton P,Earl HM,Sinnatamby R

更新日期：2011-06-01 00:00:00

abstract：:Prevention and early detection of breast cancer are the major prophylactic measures taken to reduce the breast cancer related mortality and morbidity. Clinical management of breast cancer largely relies on the efficacy of the breast-conserving surgeries and the subsequent radiation therapy. A key problem that limits t...

journal_title：Breast cancer research and treatment

authors： Nyirenda N,Farkas DL,Ramanujan VK

更新日期：2011-04-01 00:00:00

abstract：:The relationships between urinary 11-desoxy-17-oxo steroids (11-DOS), the ratio of 11-DOS to urinary 17-hydroxycorticosteroids (urinary discriminant ratio), plasma levels of the adrenal androgens dehydroepiandrosterone (DHA), DHA sulphate (DHAS), and 7 alpha-hydroxy DHA (7 alpha DHA), and tumour oestrogen receptor (ER...

journal_title：Breast cancer research and treatment

authors： Mason BH,Holdaway IM,Skinner SJ,Kay RG

更新日期：1994-01-01 00:00:00

abstract：:The aromatase inhibitors exemestane and anastrozole are approved in Japan for first-line treatment of postmenopausal patients with advanced, hormone-receptor-positive breast cancer. This phase 3, randomized, double-blind study directly compared time to progression (TTP) for exemestane and anastrozole therapy in this p...

journal_title：Breast cancer research and treatment

authors： Iwata H,Masuda N,Ohno S,Rai Y,Sato Y,Ohsumi S,Hashigaki S,Nishizawa Y,Hiraoka M,Morimoto T,Sasano H,Saeki T,Noguchi S

更新日期：2013-06-01 00:00:00

abstract：:Methylthioadenosine (MTA) phosphorylase activity was measured in 47 biopsies from primary breast cancers (n = 34) and metastatic tumors (n = 13). Most specimens were also evaluated by DNA flow cytometry and determination of estrogen and progesterone receptor contents. Median MTA phosphorylase activity was 317 pmol/mg ...

journal_title：Breast cancer research and treatment

authors： Smaaland R,Schanche JS,Kvinnsland S,Høstmark J,Ueland PM

更新日期：1987-01-01 00:00:00

abstract：:Women with diabetes have higher breast cancer incidence and mortality. The purpose of this study was to examine the impact of diabetes on stage at breast cancer diagnosis, as a possible reason for their higher mortality. Using population-based health databases from Ontario, Canada, this retrospective cohort study exam...

journal_title：Breast cancer research and treatment

authors： Lipscombe LL,Fischer HD,Austin PC,Fu L,Jaakkimainen RL,Ginsburg O,Rochon PA,Narod S,Paszat L

更新日期：2015-04-01 00:00:00

abstract：:Tamoxifen is currently the adjuvant treatment of choice for postmenopausal women with hormone-sensitive breast cancer. However, in the treatment of postmenopausal women with advanced disease, the third-generation aromatase inhibitor anastrozole ('Arimidex') has been shown to be at least as effective as tamoxifen, and ...

journal_title：Breast cancer research and treatment

authors： Aapro MS,Forbes JF

更新日期：2003-01-01 00:00:00

abstract：:The prognostic value of epidermal growth factor receptor (EGF-R) was prospectively assessed in a series of 229 clinical T1-T2, N0-N1 breast carcinomas diagnosed between May 1987 and October 1989. EGF-R expression was determined by measuring the specific Bmax of 125I EGF to tumor plasma membrane preparations. Tumor wit...

journal_title：Breast cancer research and treatment

authors： Bolla M,Chedin M,Colonna M,Marron-Charrière J,Rostaing-Puissant B,Pasquier D,Panh MH,Winckel P,Chambaz EM

更新日期：1994-01-01 00:00:00

abstract：PURPOSE:Fulvestrant is a selective estrogen receptor downregulator (SERD) that is approved for first- or second-line use as a single agent or in combination with cyclin dependent kinase or phosphatidylinositol 3-kinase inhibitors for the treatment of metastatic breast cancer. Fulvestrant exhibits exceptionally effectiv...

journal_title：Breast cancer research and treatment

authors： Wardell SE,Yllanes AP,Chao CA,Bae Y,Andreano KJ,Desautels TK,Heetderks KA,Blitzer JT,Norris JD,McDonnell DP

更新日期：2020-01-01 00:00:00

abstract：PURPOSE:The receptor activator of nuclear factor kappa B (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) axis may contribute to the development of bone metastases (BM). We studied gene expression in this pathway in primary breast cancer (BC) to determine correlations with clinical characteristics and outcomes in the n...

journal_title：Breast cancer research and treatment

authors： Vidula N,Yau C,Li J,Esserman LJ,Rugo HS

更新日期：2017-08-01 00:00:00

abstract：:To determine whether recent genome-wide association studies that reported 45 susceptibility loci in European women are also risk factors for breast cancer in Chinese women. We selected and genotyped 40 single nucleotide polymorphisms (SNPs) using the Sequenom iPlex platform in a female Chinese cohort of 2,901 breast c...

journal_title：Breast cancer research and treatment

authors： Zhang B,Li Y,Li L,Chen M,Zhang C,Zuo XB,Zhou FS,Liang B,Zhu J,Li P,Huang ZL,Xuan H,Li W,Chen ZD

更新日期：2014-08-01 00:00:00

abstract：:Previous studies on breast cancer recurrence provide a mixed picture of the quality of life of women following a recurrence. To clarify the picture, the present study addresses some previous methodological concerns by offering a multidimensional assessment with follow-up, a matched comparison group of disease-free sur...

journal_title：Breast cancer research and treatment

authors： Oh S,Heflin L,Meyerowitz BE,Desmond KA,Rowland JH,Ganz PA

更新日期：2004-09-01 00:00:00

abstract：OBJECTIVE:To examine the content, quality and reliability of YouTube videos related to breast self-examination. DESIGN:A search of YouTube was made on 21.06.2018 using the keyword of "breast self-examination". The videos were categorised by two doctors as useful information or misleading information. To evaluate the q...

journal_title：Breast cancer research and treatment

authors： Esen E,Aslan M,Sonbahar BÇ,Kerimoğlu RS

更新日期：2019-02-01 00:00:00

abstract：:Multiple adjuvant regimens are used for HER2+ breast cancer, but experience in routine practice is not reported. We evaluated whether oncologists' perceptions of these regimens matches clinical experience. We surveyed Wisconsin medical oncologists throughout the state regarding factors impacting selection of TCH (doce...

journal_title：Breast cancer research and treatment

authors： Rocque G,Onitilo A,Engel J,Pettke E,Boshoven A,Kim K,Rishi S,Waack B,Wisinski KB,Tevaarwerk A,Burkard ME

更新日期：2012-01-01 00:00:00

abstract：:In the context of neoadjuvant therapy (NT) for breast cancer patients, different targeted therapy approaches are currently evaluated in clinical trials. Serum markers could help to monitor and optimize such treatment strategies. We investigated human epidermal growth factor receptor 2 serum (sHER2) levels in 175 breas...

journal_title：Breast cancer research and treatment

authors： Witzel I,Loibl S,von Minckwitz G,Mundhenke C,Huober J,Hanusch C,Henschen S,Hauschild M,Lantzsch T,Tesch H,Latos K,Just M,Hilfrich J,Barinoff J,Eulenburg CZ,Roller M,Untch M,Müller V

更新日期：2010-09-01 00:00:00

abstract：:The mechanism of action of the pure antiestrogens ICI 164384 and ICI 182780 has been investigated. Both antagonists are steroidal antiestrogens with 7 alpha-alkylamide side-chains. The antiestrogens reduce the cellular content of the estrogen receptor by reducing the half-life of the protein. A potential mechanism for...

journal_title：Breast cancer research and treatment

authors： Parker MG

更新日期：1993-01-01 00:00:00